Kusunokinin ((-)-Kusunokinin; 7 and 14 mg/kg; i.h.; 3 times a week for 2 weeks) attenuates tumor growth in NMU-induced breast cancer rats through the down-regulation of signaling molecules (c-Src, PI3K, Akt and Erk1/2)[1].
| Animal Model: | Female Sprague Dawley rats (7 weeks of age)[1] |
| Dosage: | 7 and 14 mg/kg |
| Administration: | Subcutaneous injection, 3 times a week for 2 weeks |
| Result: | Inhibited the mammary tumor growth and decreased tumor volume.
Down-regulated c-Src, Erk1/2 and PI3K proteins and decreased Akt proteins.
Inhibited downstream molecules in the cell cycle (c-Myc, E2f-1, CDK1 and cyclin B1) and metastasis (E-cadherin, MMP-2 and MMP-9).
|
![(3R,4R)-3-[(1,3-Benzodioxole-5-yl)methyl]-4-(3,4-dimethoxybenzyl)-4,5-dihydrofuran-2(3H)-one Structure](/CAS/20180906/GIF/58311-20-9.gif)